Use of a CD28 binding substance for the production of a pharmaceutical composition with dose-dependent efficacy
DE10352900A1
Method of making pharmaceutical composition for treatment of illnesses associated with deficient costimulation ability of T-cells, employs superagonistic monoclonal antibody
DE10345008A1
Using superagonist, CD28-specific monoclonal antibodies, or their mimics, for treatment and prevention of autoimmune inflammation and for immune system reconstitution
AU2002357427A1
Peptide or protein containing a c'-d loop of the cd28 receptor family
DE10230223A1
Microparticles with CD28-specific monoclonal antibodies
DE10212108A1
Use of an active substance that binds to CD28 for the production of a pharmaceutical composition
